Search - tctmd.com

Displaying 41 - 60 of 113

Sort: Relevancy | Date

News Daily News

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

Shelley Wood

September 24, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

News Conference News SCAI 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

L.A. McKeown

April 26, 2018

News Daily News

Uncomplicated TLR After PCI Linked With Worse Mortality

Michael O'Riordan

April 20, 2018

News Industry News

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

March 21, 2018

News Industry News

Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels

February 26, 2018

News Daily News

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Yael L. Maxwell

February 20, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

Presentation

Optimized Screening of CAD With Invasive Coronary Angiography and Ad Hoc PCI During TAVR

August 10, 2017

News Daily News

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

Leah Lawrence

August 10, 2017

Advertisement

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

Uncomplicated TLR After PCI Linked With Worse Mortality

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Positive Five-Year Data Published for MiStent in EuroIntervention

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Long-term Absorb BVS Data Continue to Disappoint

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Optimized Screening of CAD With Invasive Coronary Angiography and Ad Hoc PCI During TAVR

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content